Abstract
Chronic GVHD (cGVHD) associated bronchiolitis obliterans syndrome (BOS) is a serious complication after allo-SCT, and lung transplantation (LTx) may be the ultimate treatment option. To evaluate this treatment, data on all patients with LTx after allo-SCT ever performed in Sweden, Norway, Denmark and Finland were recorded and compared with survival data from the Scandiatransplant registry. In total, LTx after allo-SCT had been performed in 13 patients. Allo-SCT was done because of AML (n=6), CML (n=3), ALL (n=2), immunodeficiency (n=1) and aplastic anemia (n=1). All developed clinical cGVHD, with median interval from allo-SCT to LTx of 8.2 (0.7–16) years. Median age at LTx was 34 (16–55) years, and the median postoperative observation time was 4.2 (0.1–15) years. Two patients died, one due to septicemia, the other of relapsing leukemia, after 2 and 14 months, respectively. Four developed BOS, one of these was retransplanted. The survival did not significantly differ from the survival in matched LTx controls, being 90% 1 year and 75% 5 years after LTx compared with 85% and 68% in the controls. We therefore suggest that LTx may be considered in carefully selected patients with BOS due to cGVHD after allo-SCT.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945–956.
Baird K, Pavletic SZ . Chronic graft versus host disease. Curr Op Hematol 2006; 13: 426–435.
Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Bone Marrow Transplant 2012; 47: 337–341.
Sakaida E, Nakaseko C, Harima A, Yokota A, Cho R, Saito Y et al. Late-onset noninfectious pulmonary complications after allogeneic stem cell transplantation are significantly associated with chronic graft-versus-host disease and with the graft-versus-leukemia effect. Blood 2003; 102: 4236–4242.
Lund MB, Brinch L, Kongerud J, Boe J . Lung function 5 yrs after allogeneic bone marrow transplantation conditioned with busulphan and cyclophosphamide. Eur Resp J 2004; 23: 901–905.
Vos R, Vanaudenaerde BM, Ottevaere A, Verleden SE, De Vleeschauwer SI, Willems-Widyastuti A et al. Long-term azithromycin therapy for bronchiolitis obliterans syndrome: Divide and conquer? J Heart Lung Transplant 2010; 29: 1358–1368.
Chien JW, Duncan S, Williams KM, Pavletic SZ . Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2010; 16 (1 Suppl): S106–S114.
Martin PJ, Chien JW . What we know and mostly do not know about bronchiolitis obliterans syndrome. Bone Marrow Transplant 2012; 47: 1–4.
Lucid CE, Savani BN, Engelhardt BG, Shah P, Clifton C, Greenhut SL et al. Extracorporeal photopheresis in patients with refractory bronchiolitis obliterans developing after allo-SCT. Bone Marrow Transplant 2011; 46: 426–429.
Redel-Montero J, Bujalance-Cabrera C, Vaquero-Barrios J-M, Santos-Luna F, Arenas-De Larriva M, Moreno-Casado P et al. Lung transplantation for bronchiolitis obliterans after allogenic bone marrow transplantation. Transplant Proc 2010; 42: 3023–3025.
Rabitsch W, Deviatko E, Keil F, Herold C, Dekan G, Greinix HT et al. Successful lung transplantation for bronchiolitis obliterans after allogeneic marrow transplantation. Transplantation 2001; 71: 1341–1343.
Whitson BA, Shelstad RC, Hertz MI, Kelly RF, D’aposCunha J, Shumway SJ . Lung transplantation after hematopoietic stem cell transplantation. Clin Transplant 2012; 26: 254–258.
Chiang KY, Lazarus HM . Should we be performing more combined hematopoietic stem cell plus solid organ transplants? Bone Marrow Transplant 2003; 31: 633–642.
Christie JD, Edwards LB, Kucheryavaya AY, Benden C, Dobbels F, Kirk R et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Lung and Heart-Lung Transplant Report—2011. J Heart Lung Transplant 2011; 30: 1104–1122.
Koenecke C, Hertenstein B, Schetelig J, Van Biezen A, Dammann E, Gratwohl A et al. Solid organ transplantation after allogeneic hematopoietic stem cell transplantation: a retrospective, multicenter study of the EBMT. Am J Transplant 2010; 10: 1897–1906.
Orens J, Estenne M, Arcasoy S, Conte J, Corris P, Egan J et al. International guidelines for the selection of lung transplant candidates: 2006 update-a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25: 745–755.
Ustun C, Miller JS, Munn DH, Weisdorf DJ, Blazar BR . Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? Blood 2011; 118: 5084–5095.
Palmer SM, Limaye AP, Banks M, Gallup D, Chapman J, Lawrence EC et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann Intern Med 2010; 152: 761–769.
Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15: 1143–1238.
Acknowledgements
We thank Ulla Nyström at Scandiatransplant for help with the data from the registry and to Helen Baldoremo at the EBMT Transplant Activity Survey office for providing background data on allo-SCT.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Holm, A., Riise, G., Hansson, L. et al. Lung transplantation for bronchiolitis obliterans syndrome after allo-SCT. Bone Marrow Transplant 48, 703–707 (2013). https://doi.org/10.1038/bmt.2012.197
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2012.197
Keywords
This article is cited by
-
Diagnosis and treatment of bronchiolitis obliterans syndrome accessible universally
Bone Marrow Transplantation (2019)
-
Solid organ transplantation following allogeneic haematopoietic cell transplantation: experience from a referral organ transplantation center and systematic review of literature
Bone Marrow Transplantation (2019)
-
Lung transplantation for bronchiolitis obliterans syndrome after allogenic hematopoietic stem cell transplantation
Frontiers of Medicine (2018)
-
Komplikationen der allogenen Knochenmark- und Stammzelltransplantation
Der Internist (2014)
-
Update to the guidelines for selection of lung-transplant candidates
Current Respiratory Care Reports (2014)